Lista de obras - Annamaria Brioli - Dominio Público Uruguay

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

artículo científico publicado en 2007

Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.

artículo científico publicado en 2013

Biology and treatment of myeloma

artículo científico

Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.

artículo científico publicado en 2013

Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.

artículo científico publicado en 2015

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

article

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2012

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

artículo científico publicado en 2014

Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

scientific article published on 10 July 2020

Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.

artículo científico publicado en 2013

Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.

artículo científico publicado en 2015

Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

artículo científico publicado en 2007

First line vs delayed transplantation in myeloma: Certainties and controversies

artículo científico publicado en 2016

Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)

scientific article published on 02 December 2019

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

artículo científico publicado en 2020

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

artículo científico publicado en 2013

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.

artículo científico publicado en 2014

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

scientific article published on 02 July 2013

Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease

artículo científico publicado en 2012

Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma

artículo científico publicado en 2011

Maintenance therapy in newly diagnosed multiple myeloma: current recommendations

artículo científico publicado en 2014

Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis

scientific article published on 31 March 2011

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

artículo científico publicado en 2015

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

artículo científico publicado en 2006

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.

artículo científico publicado en 2015

Patient with ataxia telangiectasia who developed acute myeloid leukemia

artículo científico publicado en 2011

Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma

artículo científico publicado en 2014

Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

artículo científico publicado en 2011

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

artículo científico publicado en 2013

Role of consolidation therapy in transplant eligible multiple myeloma patients

artículo científico

Safety issues and management of toxicities associated with new treatments for multiple myeloma.

artículo científico publicado en 2017

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

artículo científico publicado en 2014

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

artículo científico publicado en 2009

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

article

Thalidomide maintenance in multiple myeloma: certainties and controversies

artículo científico publicado en 2009

Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency

artículo científico publicado en 2010

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML

scientific article published on 01 October 2019

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

artículo científico publicado en 2015

The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.

artículo científico

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

article

The impact of response on bone-directed therapy in patients with multiple myeloma.

artículo científico publicado en 2013

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey

scientific article published on 24 January 2019

The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma.

artículo científico publicado en 2014

The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients.

artículo científico publicado en 2013

Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.

artículo científico

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

artículo científico publicado en 2014

Lista de obras de Annamaria Brioli

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.

Biology and treatment of myeloma

Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.

Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.

Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.

Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

First line vs delayed transplantation in myeloma: Certainties and controversies

Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease

Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma

Maintenance therapy in newly diagnosed multiple myeloma: current recommendations

Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.

Patient with ataxia telangiectasia who developed acute myeloid leukemia

Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma

Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

Role of consolidation therapy in transplant eligible multiple myeloma patients

Safety issues and management of toxicities associated with new treatments for multiple myeloma.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

Thalidomide maintenance in multiple myeloma: certainties and controversies

Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow

The impact of response on bone-directed therapy in patients with multiple myeloma.

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey

The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma.

The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients.

Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients